SATB2 expression in human tumors: A tissue microarray study on more than 15,000 tumors

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S109-S109
Author(s):  
D Dum ◽  
T Krech
Keyword(s):  
Cell Carcinoma ◽  
Tissue Microarray ◽  
Cancer Progression ◽  
Papillary Renal Cell Carcinoma ◽  
Tumor Location ◽  
Nodal Metastasis ◽  
Neuroendocrine Neoplasms ◽  
Braf Mutations ◽  
Tumor Tissues ◽  
Tumor Types

Abstract Introduction/Objective Introduction: Special AT-rich sequence-binding protein 2 (SATB2) binds to DNA in specific nuclear matrix attachment regions and facilitates chromatin remodeling. SATB2 immunostaining is commonly used as a marker for colorectal adenocarcinoma and osteosarcoma. Methods/Case Report Methods: To comprehensively evaluate SATB2 expression in normal and tumor tissues, a tissue microarray containing 15,012 samples from 120 different tumor types and subtypes and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. Results (if a Case Study enter NA) Result: SATB2 positivity was found in 89 different tumor types including 59 with at least one moderately positive and 38 tumor types with at least one strongly positive tumor. Most frequent and strongest expression were found in adenomas (94-96%), adenocarcinomas (86%) and various subtypes of neuroendocrine neoplasms (43-100%) of the colorectum and appendix, Merkel cell carcinoma (74%), osteosarcomas (60%), and papillary renal cell carcinoma (RCC) (52%). In colorectal cancer, weak SATB2 expression was linked to high pT (p<0.0001), nodal metastasis (p<0.0001), right-sided tumor location (p<0.0001), microsatellite instability (p=0.0004), and BRAF mutations (p<0.0224). In papillary RCC, low SATB2 was associated with high pT (p=0.0197), distant metastasis (p=0.042), and reduced tumor specific survival (p=0.0395). In clear cell RCC, low SATB2 was linked to high pT (p<0.0001), high UICC stage (p<0.0001), high Thoenes grade (p=0.0178), and reduced recurrence free survival (p=0.0216). Conclusion SATB2 expression can occur in many different tumor entities. Strong SATB2 expression argues for a colorectal tumor origin within adenocarcinomas and neuroendocrine neoplasms. Weak SATB2 expression reflects cancer progression and poor prognosis in colorectal and kidney cancer.

scholarly journals MPC-06 LRG1 HAS MULTIPLE POTENTIAL FOR CLINICOPATHOLOGICAL BIOMARKER OF GLIOBLASTOMA

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii23-ii23
Author(s):  
Takuya Furuta ◽  
Yasuo Sugita ◽  
Satoru Komaki ◽  
Kouichi Ohshima ◽  
Motohiro Morioka ◽  
...  
Keyword(s):  
Extent Of Resection ◽  
Tumor Location ◽  
High Expression ◽  
Karnofsky Performance Scale ◽  
Lower Grade ◽  
Diffuse Glioma ◽  
Tumor Tissues ◽  
Lower Grade Glioma ◽  
Expression Rate ◽  
Tumor Types

Abstract BACKGROUND AND AIM Leucine-rich α-2 glycoprotein 1 (LRG1) is one of the candidate proteins as a diagnostic marker for glioblastoma. Although association with angiogenesis has been reported, it has been suggested that the role as a biomarker differs depending on the tumor types. The role of LRG1 as a biomarker in glioblastoma was examined clinicopathologically. METHODS Tumor tissues of 156 cases diagnosed as diffuse glioma (27 astrocytomas, 15 oligodendrogliomas, 114 glioblastomas) according to WHO 2016 classification at Kurume University from January 2001 to April 2019 were used. The immunohistochemical intensity of LRG1 was scoring as 4 stages and classified into 2 groups; score 0–1 was defined as low expression and score 2–3 was defined as high expression. Mutations of IDH1/2 and TERT promoter were analyzed by Sanger method. In glioblastoma, the relationship between LRG1 expression and clinical parameters such as age, preoperative Karnofsky Performance Scale, tumor location, extent of resection, MGMT promoter, and prognosis were examined. RESULTS LRG1 high expression rate was 41.2% (47/114) in glioblastoma, 3.7% (1/27) in astrocytoma, 20% (3/15) in oligodendroglioma, and glioblastoma showed significant higher expression level of LRG1 compared with lower-grade glioma (p = 0.0003). High expression of LRG1 was an independent favorable prognostic factor (HR 0.41, 95% CI 0.18–0.86, p=0.019) in IDH-wildtype glioblastoma, and correlated with gross total resection (p = 0.002) and the tumor location of the non-subventricular zone (SVZ) (p = 0.00007). CONCLUSION LRG1 demonstrated multiple potential as diagnostic, prognostic, and regional biomarker for glioblastoma.

scholarly journals Common Pitfalls in Ewing Sarcoma and Desmoplastic Small Round Cell Tumor Diagnosis Seen in a Study of 115 Cases

2021 ◽  
Vol 9 (4) ◽  
pp. 62
Author(s):  
Nikolaos A. Trikalinos ◽  
John S. A. Chrisinger ◽  
Brian A. Van Tine
Keyword(s):  
Ewing Sarcoma ◽  
Tumor Location ◽  
Neuroendocrine Neoplasms ◽  
Round Cell ◽  
Contributing Factors ◽  
Small Round Cell ◽  
Diagnostic Pitfall ◽  
Inappropriate Treatment ◽  
Tertiary Center ◽  
Tumor Types

Ewing sarcoma (ES), “Ewing-like sarcoma” (ELS) and desmoplastic small round cell tumors (DSRCT) can masquerade as other tumor types, particularly neuroendocrine neoplasms and receive inappropriate treatment. We retrieved 115 cases of ES, ELS and DSRCT seen over 17 years in a tertiary center. An initial misdiagnosis or incomplete diagnosis occurred in 6/93 (6.4%) of ES/ELS and 5/22 (22.7%) of DSRCT cases. The most frequent misdiagnosis was small cell neuroendocrine carcinoma. While any misdiagnosis or incomplete classification is almost certainly multifactorial, the most common identified reason for erroneous/incomplete initial reporting was expression of neuroendocrine markers. Other contributing factors included keratin expression, older patient age and apparently unusual tumor location. Most patients treated with a non-sarcoma chemotherapy regimen expired, while those who received a sarcoma-related regimen were alive as of last evaluation. Increased awareness of this diagnostic pitfall is needed in evaluating cases of round cell malignancies.

scholarly journals Papillary Renal Cell Carcinoma with Extensive Paraaortic Nodal Metastasis Mimicking Malignant Lymphoma

2011 ◽  
Vol 10 (3) ◽  
pp. 201-204 ◽  
Author(s):  
Toshimichi MITSUFUJI ◽  
Ritsuko FUJIMITSU ◽  
Mikiko IDA ◽  
Hiroshi URAKAWA ◽  
Shin-ichi KORA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Malignant Lymphoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Nodal Metastasis

scholarly journals MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples

2021 ◽  
Vol 20 ◽  
pp. 153303382110433
Author(s):  
Sebastian Dwertmann Rico ◽  
Moritz Mahnken ◽  
Franziska Büscheck ◽  
David Dum ◽  
Andreas M. Luebke ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Gastric Adenocarcinoma ◽  
Tissue Microarray ◽  
Bronchioloalveolar Carcinoma ◽  
Ductal Adenocarcinoma ◽  
Cell Renal Cell Carcinoma ◽  
Ampullary Adenocarcinoma ◽  
Tissue Samples ◽  
Tumor Types ◽  
Tumor Entities

Background: Mucin 5AC (MUC5AC) belongs to the glycoprotein family of secreted gel-forming mucins and is physiologically expressed in some epithelial cells. Studies have shown that MUC5AC is also expressed in several cancer types suggesting a potential utility for the distinction of tumor types and subtypes. Methods: To systematically determine MUC5AC expression in normal and cancerous tissues, a tissue microarray containing 10 399 samples from 111 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Results: MUC5AC was expressed in normal mucus-producing cells of various organs. At least weak MUC5AC positivity was seen in 44 of 111 (40%) tumor entities. Of these 44 tumor entities, 28 included also tumors with strong positivity. MUC5AC immunostaining was most commonly seen in esophageal adenocarcinoma (72%), colon adenoma (62%), ductal adenocarcinoma of the pancreas (64%), mucinous carcinoma of the ovary (46%), diffuse gastric adenocarcinoma (44%), pancreatic ampullary adenocarcinoma (41%), intestinal gastric adenocarcinoma (39%), and bronchioloalveolar carcinoma (33%). Clinically relevant tumors with complete or almost complete absence of MUC5AC staining included small cell carcinoma of the lung (0% of 17), clear cell renal cell carcinoma (0% of 507), papillary thyroid carcinoma (0% of 359), breast cancer (2% of 1097), prostate cancer (2% of 228), soft tissue tumors (0.1% of 968), and hematological neoplasias (0% of 111). Conclusion: The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.

scholarly journals DOG1 expression is in common human tumors: A tissue microarray study on more than 15,000 tissue samples

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S108-S109
Author(s):  
K Jansen ◽  
S Steurer
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tissue Microarray ◽  
Squamous Cell ◽  
Normal Tissue ◽  
Hpv Infection ◽  
Receptor Expression ◽  
Ductal Adenocarcinoma ◽  
Tumor Types ◽  
Tumor Entities

Abstract Introduction/Objective Introduction: DOG1 (Discovered on GIST1) is a voltage-gated calcium-activated chloride and bicarbonate channel that is highly expressed in interstitial cells of Cajal and in gastrointestinal stromal tumors (GIST) derived from Cajal cells. Methods/Case Report Methods: To systematically determine in what tumor entities and normal tissue types DOG1 may be further expressed, a tissue microarray (TMA) containing 15,965 samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Results (if a Case Study enter NA) Results: DOG1 immunostaining was found in 67 tumor types including GIST (95.7%), esophageal squamous cell carcinoma (31.9%), pancreatic ductal adenocarcinoma (33.6%), adenocarcinoma of the Papilla Vateri (20%), squamous cell carcinoma of the vulva (15.8%) and the oral cavity (15.3%), mucinous ovarian cancer (15.3%), esophageal adenocarcinoma (12.5%), endometrioid endometrial cancer (12.1%), neuroendocrine carcinoma of the colon (11.1%) and diffuse gastric adenocarcinoma (11%). Low level-DOG1 immunostaining was seen in 17 additional tumor entities. DOG1 expression was unrelated to histopathological parameters of tumor aggressiveness and/or patient prognosis in cancers of the breast (n=1,002), urinary bladder (975), ovary (469), endometrium (173), stomach (233), and thyroid gland (512). Conclusion High DOG1 expression was linked to estrogen receptor expression in breast cancer (p<0.0001) and absence of HPV infection in squamous cell carcinomas (p=0.0008). In conclusion, our data identify several tumor entities that can show DOG1 expression levels at similar levels as in GIST. Although DOG1 is tightly linked to a diagnosis of GIST in spindle cell tumors, the differential diagnosis is much broader in DOG1 positive epithelioid neoplasms.

scholarly journals BRAF-activated non-protein coding RNA (BANCR) advances the development of esophageal squamous cell carcinoma via cell cycle

2017 ◽  
Vol 12 (1) ◽  
pp. 128-134
Author(s):  
Chunxia Yang ◽  
Yue Wang ◽  
Fangjun Chen ◽  
Yongzhong Hou ◽  
Jianhua Jin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Progression ◽  
Squamous Cell ◽  
Negative Control ◽  
Protein Coding ◽  
Cell Cycles ◽  
Normal Tissues ◽  
Tumor Tissues

AbstractEsophageal carcinoma is one of the important lethal tumors in the world, but the mechanism of esophageal cancer progression is still unclear. The long non-coding RNAs are known to regulate tumor progression. Here we report that BRAF-activated nonprotein coding RNA (BANCR) is associated with the development of esophageal squamous cell carcinoma (ESCC). The expression levels ofBANCRin 132 ESCC tumor tissues detected by quantitative real-time PCR were significantly higher than that in the adjacent normal tissues. The expression level ofBANCRwas down-regulated by transfecting small interrupting RNA againstBANCR(BANCRsiRNA) in Eca109 cells. Eca109 and TE-1 cells transfected withBANCRsiRNA led to the delayed cell cycles compared to the cells transfected with negative control siRNA. Moreover, MTT assays demonstrated that Eca109 cells transfected withBANCRsiRNA resulted in the inhibition of cell proliferation. These results suggested thatBANCRadvances the development and progression of ESCC cells through regulating their cell cycles.

scholarly journals Napsin A Expression in Human Tumors and Normal Tissues

2021 ◽  
Vol 27 ◽  
Author(s):  
Sören Weidemann ◽  
Jan Lukas Böhle ◽  
Hendrina Contreras ◽  
Andreas M. Luebke ◽  
Martina Kluth ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Aspartic Proteinase ◽  
Clear Cell Adenocarcinoma ◽  
Cell Renal Cell Carcinoma ◽  
Napsin A ◽  
Tumor Types

Background: Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.Methods: To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.Results: Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (p ≤ 0.03).Conclusion: This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas.

scholarly journals Diagnostic and Prognostic Impact of Cytokeratin 18 Expression in Human Tumors: A Tissue Microarray Study on 11,952 Tumors

2020 ◽  
Author(s):  
Anne Menz ◽  
Timo Weitbrecht ◽  
Franziska Büscheck ◽  
Andreas M Luebke ◽  
Martina Kluth ◽  
...  
Keyword(s):  
Tissue Microarray ◽  
Cancer Progression ◽  
Squamous Cell ◽  
Renal Cell ◽  
Precursor Cells ◽  
Squamous Cell Carcinomas ◽  
Intermediate Filament Protein ◽  
Type I ◽  
Prognostic Impact ◽  
Tumor Types

Abstract BackgroundCytokeratin 18 (CK18) is an intermediate filament protein of the cytokeratin acidic type I group and is primarily expressed in single-layered or “simple” epithelial tissues and carcinomas of different origin. MethodsTo systematically determine CK18 expression in normal and cancerous tissues, 11,952 tumor samples from 115 different tumor types and subtypes (including carcinomas, mesenchymal and biphasic tumors) as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format. ResultsCK18 was expressed in normal epithelial cells of most organs but absent in normal squamous epithelium. At least an occasional weak CK18 positivity was seen in 90 of 115 (78.3%) tumor types. Wide-spread CK18 positivity was seen in 37 (31.9%) of tumor entities, including adenocarcinomas of the lung, prostate, colon and pancreas as well as ovarian cancer. Tumor categories with variable CK18 immunostaining included cancer types arising from CK18 positive precursor cells but show CK18 downregulation in a fraction of cases, tumor types arising from CK18 negative precursor cells occasionally exhibiting CK18 neo-expression, tumors derived from normal tissues with variable CK18 expression, and tumors with a mixed differentiation. CK18 downregulation was for example seen in renal cell cancers and breast cancers, whereas CK18 neo-expression was found in squamous cell carcinomas of various origins. Down-regulation of CK18 in invasive breast carcinomas of no special type and clear cell renal cell carcinomas (ccRCC) was related to adverse tumor features in both tumors (p≤0.001) and poor patient prognosis in ccRCC (p=0.0088). Up-regulation of CK18 in squamous cell carcinomas was linked to high grade and lymph node metastasis (p<0.05). In summary, CK18 is consistently expressed in various epithelial cancers, especially adenocarcinomas. ConclusionsDown-regulation or loss of CK18 expression in cancers arising from CK18 positive tissues as well as CK18 neo-expression in cancers originating from CK18 negative tissues is linked to cancer progression and may reflect tumor dedifferentiation.

Sign in / Sign up

Export Citation Format

Share Document